Wave Life Sciences Surges 55% After Achieving First-Ever Therapeutic RNA Editing in RestorAATion-2 Trial

Oct 16, 2024, 12:32 PM

Wave Life Sciences announced a significant milestone in RNA editing, achieving the first-ever therapeutic RNA editing in humans. The breakthrough was achieved in the RestorAATion-2 trial of WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD). A single subcutaneous dose of WVE-006 in the first two patients with homozygous 'ZZ' AATD resulted in mean plasma total AAT levels of approximately 11 micromolar, with mean wild-type M-AAT representing 6% of the total. This development led to a 55% surge in Wave Life Sciences' stock price. Additionally, the company has announced a Virtual Research Day on October 30, 2024.